BrainLife | Library
CNS Tumors
Diffuse astrocytic and oligodendroglial tumors
Anaplastic astrocytoma


Home > Library > CNS Tumors > Diffuse astrocytic and oligodendroglial tumors > Anaplastic astrocytoma


Contents



CASE REPORTS


CLASSIFICATION


DIAGNOSIS


EPIDEMIOLOGY, RISK FACTORS


ETIOLOGY, PATHOGENESIS, PATHOLOGY


FOLLOW-UP, QUALITY OF LIFE


INTEGRATIVE MEDICINE


OVERALL MANAGEMENT


PROGNOSIS


TREATMENT





Case reports



Sali G, Briggs RG, Conner AK, Palejwala AH, Fung KM, Battiste JD, Sughrue ME.
Co-occurrence of astrocytoma and astroblastoma: Case report and literature review.
Neuropathology. 2018 Oct;38(5):516-520. doi: 10.1111/neup.12483. Online 2018 Jun 25. _



BONE METASTASES



Li ZG, Mu HY.
Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article.
Medicine (Baltimore). 2017 Jun;96(23):e7123. doi: 10.1097/MD.0000000000007123. Online 2017 Jun 8. _



LONG-TERM DAILY TEMOZOLOMIDE



Zhou Z, Howard TA, Villano JL.
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Cancer Chemother Pharmacol. 2017 Aug 8. doi: 10.1007/s00280-017-3415-5. Online first. _



Overall management


Review

Caccese M, Padovan M, D'Avella D, Chioffi F, Gardiman MP, Berti F, Busato F, Bellu L, Bergo E, Zoccarato M, Fassan M, Zagonel V, Lombardi G.
Anaplastic Astrocytoma: State of the art and future directions.
Crit Rev Oncol Hematol. 2020 Jul 17. 2020;153:103062. doi: 10.1016/j.critrevonc.2020.103062. _



Case report
Review

Takamiya S, Hatanaka KC, Ishi Y, Seki T, Yamaguchi S.
Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature.
Neuropathology. 2020 Jan 27. 2020;10.1111/neup.12636. doi: 10.1111/neup.12636. _



Prognosis




OVERVIEW



Shin JY, Diaz AZ.
Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy.
J Neurooncol. 2016 Jul 11. doi: 10.1007/s11060-016-2210-1. _



TEMOZOLOMIDE



Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA.
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
J Neurooncol. 2016 Mar;127(1):165-71. doi: 10.1007/s11060-015-2028-2. Online 2016 Jan 4. _



Treatment



Berghoff A, van den Bent M.
How I treat anaplastic glioma without 1p/19q codeletion.
ESMO Open. 2019 Aug 20;4(Suppl 2):e000534. doi: 10.1136/esmoopen-2019-000534. _




Schiff D.
Benefit with adjuvant chemotherapy in anaplastic astrocytoma.
Lancet. 2017 Aug 8. doi: 10.1016/S0140-6736(17)31477-0. Online first. _
Referring to: van den Bent MJ et al., Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Aug 8. doi: 10.1016/S0140-6736(17)31442-3. Online first. _




Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG).
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Acta Oncol. 2017 Jul 4:1-10. doi: 10.1080/0284186X.2017.1332780. Online first. _




van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet. 2017 Aug 8. doi: 10.1016/S0140-6736(17)31442-3. Online first. _




Wu J, Zou T, Bai HX, Li X, Zhang Z, Xiao B, Nasrallah M, Karakousis G, Cao Y, Zhang PJ, Yang L.
Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma.
Oncotarget. 2017 Apr 26. doi: 10.18632/oncotarget.17441. Online first. _